Organization
Chiba, Japan
5 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Disaster Medical Center, Tokyo, Japan, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa-Shi, Japan Association for Development of Community Medicine, Graduate School of Medicine Chiba University, Chiba, Japan,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
Effect of lymph node dissection and adjuvant therapy in patients with sentinel node+ melanoma: An observational multicenter study.Org: National Cancer Center Hospital East, Kashiwa, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine, Nagoya University Graduate School of Medicine, Aichi Cancer Center Hospital,